These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38279126)
1. The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis. Elfar S; Mahmoud SA; Hamdi S; Emad AA; Abd-ElGawad M; Taha NA BMC Cardiovasc Disord; 2024 Jan; 24(1):74. PubMed ID: 38279126 [TBL] [Abstract][Full Text] [Related]
2. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis. Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Patel SM; Braunwald E; Steffel J; Boriani G; Palazzolo MG; Antman EM; Bohula EA; Carnicelli AP; Connolly SJ; Eikelboom JW; Gencer B; Granger CB; Morrow DA; Patel MR; Wallentin L; Ruff CT; Giugliano RP; Circulation; 2024 Mar; 149(12):932-943. PubMed ID: 38264923 [TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355 [TBL] [Abstract][Full Text] [Related]
5. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404 [TBL] [Abstract][Full Text] [Related]
6. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. Patti G; Di Gioia G; Cavallari I; Nenna A Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964 [TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140 [TBL] [Abstract][Full Text] [Related]
10. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644 [TBL] [Abstract][Full Text] [Related]
11. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694 [TBL] [Abstract][Full Text] [Related]
12. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP; Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354 [TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis. Barbarawi M; Barbarawi O; Corcoran J; Obeidat K; Al-Abdouh A; Mhanna M; Al Kasasbeh M; Pickett CC Curr Probl Cardiol; 2022 Nov; 47(11):101346. PubMed ID: 35932849 [TBL] [Abstract][Full Text] [Related]
16. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN J Cardiol; 2018 Aug; 72(2):105-112. PubMed ID: 29519547 [TBL] [Abstract][Full Text] [Related]
17. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. Kido K; Ngorsuraches S Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979 [TBL] [Abstract][Full Text] [Related]
18. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation. Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582 [TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]